Myogen presents additional results from phase 2b clinical trial of darusentan

By Lisa Kerner

Erie, Pa., May 16 - Myogen, Inc. presented additional results from its phase 2b clinical trial of its endothelin receptor antagonist darusentan in patients with resistant hypertension in a poster session at the American Society of Hypertension conference in New York.

The poster, entitled "Darusentan Reduces 24-hour Ambulatory Blood Pressure in Patients with Resistant Hypertension," demonstrated results of a secondary endpoint of the trial, ambulatory blood pressure in patients.

Darusentan produced statistically significant reductions in trough sitting blood pressure as measured by syhygmomanometry in 115 patients with resistant hypertension, according to a news release.

In the randomized, double-blind, multi-center center, patients received two-weeks of placebo followed by darusentan or placebo once daily for 10 weeks. Doses escalated every two weeks from 10 mg to a maximum dose of 300 mg.

Denver-based Myogen discovers, develops and commercializes small molecule therapeutics for the treatment of cardiovascular disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.